Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FORADIL CERTIHALER vs AEROLATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Formoterol is a long-acting beta2-adrenergic receptor agonist that stimulates intracellular adenyl cyclase, increasing cyclic AMP production and causing bronchodilation.
Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.
Long-term maintenance treatment of asthma,Prevention of exercise-induced bronchospasm,Maintenance treatment of chronic obstructive pulmonary disease (COPD)
FDA-approved: Treatment of asthma and chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity, bradycardia in preterm infants
One inhalation (12 mcg) twice daily via oral inhalation.
For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.
The terminal elimination half-life of formoterol (active component) ranges from 5 to 10 hours following inhalation. This supports twice-daily dosing, though clinical effect may persist longer due to prolonged receptor binding.
Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days
Formoterol is extensively metabolized by direct glucuronidation via UGT1A1, UGT1A3, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT2B7, and UGT2B15, and O-demethylation via CYP2D6 and CYP2C19.
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by xanthine oxidase and N-acetyltransferase. Metabolites excreted renally.
After oral inhalation, the majority of a dose is excreted in feces (up to 70%) as unchanged drug and metabolites via biliary elimination. Renal excretion accounts for approximately 13-25% of the dose, primarily as metabolites. Unabsorbed drug accounts for the remainder.
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites), 5% other
Formoterol is approximately 60-70% bound to plasma proteins (primarily albumin).
65% bound to albumin
The volume of distribution (Vd) of formoterol is approximately 3.4 L/kg, indicating extensive distribution into tissues beyond plasma.
2.5 L/kg (extensive tissue distribution, suggests high lung penetration)
Inhaled bioavailability is highly variable, approximately 20-30% of the inhaled dose reaches the lungs. Oral bioavailability is low (<10%) due to first-pass metabolism. The swallowed portion contributes minimally to systemic levels.
Oral: 40% (first-pass metabolism); Inhaled: 20% (lung deposition)
No dosage adjustment required for renal impairment. Use with caution in severe impairment.
No dose adjustment required for renal impairment. Drug is primarily hepatically metabolized and renally excreted as inactive metabolites; however, significant accumulation is not expected in renal dysfunction.
No dosage adjustment recommended; pharmacokinetics unaffected by mild to moderate hepatic impairment.
Child-Pugh Class A: No dose adjustment. Class B: Reduce dose to 50% of normal, monitor for adverse effects. Class C: Use with caution; reduce dose to 25-50% and monitor closely. Specific data for AEROLATE limited; adjust based on clinical response and tolerance.
For children 5 years and older: one inhalation (12 mcg) twice daily. Safety and efficacy in children under 5 not established.
Children 4-11 years: 1-2 inhalations (90 mcg each) twice daily; maximum 2 inhalations twice daily. Children 12 years and older: Same as adult dosing. Administer via inhaler with spacer for optimal delivery. Weight-based dosing not typically used; fixed doses per age group.
No specific dose adjustment; monitor for adverse effects due to potential age-related comorbidities.
No specific dose adjustment required. Use lowest effective dose due to potential for increased systemic exposure from reduced clearance and higher risk of adverse effects (e.g., osteoporosis, hyperglycemia). Monitor for cardiac effects and adrenal suppression.
Long-acting beta2-adrenergic agonists increase the risk of asthma-related death; Foradil should only be used as add-on therapy for patients not adequately controlled on other asthma controllers or whose disease severity warrants initiation of a LABA.
No FDA black box warning.
Asthma-related death,Deterioration of disease,Use of anti-inflammatory agents,Paradoxical bronchospasm,Cardiovascular effects,Hypokalemia,Hyperglycemia,Immediate hypersensitivity reactions
Monitor serum theophylline levels due to narrow therapeutic index (10-20 mcg/m L).,Risk of toxicity at high levels: seizures, arrhythmias, death.,Use with caution in patients with hepatic impairment, heart failure, fever, or elderly.,Cigarette smoking and certain drugs (e.g., rifampin, phenytoin) induce metabolism; others (e.g., cimetidine, macrolides) inhibit metabolism.
Treatment of status asthmaticus or other acute episodes of asthma,Hypersensitivity to formoterol fumarate or any inactive ingredients
Hypersensitivity to theophylline or any component.,Active peptic ulcer disease.,Uncontrolled seizure disorders.
No known food interactions. Formoterol may increase blood glucose, so monitor if diabetic. Avoid high-fat meals if using with certain devices? Not applicable.
Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may potentiate CNS stimulation and toxicity. Food does not significantly affect absorption, but high-fat meals may delay absorption. Consistent dietary habits are recommended.
Formoterol fumarate (FORADIL CERTIHALER) is classified as FDA Pregnancy Category C. In animal studies, formoterol caused fetal malformations (e.g., omphalocele, skeletal abnormalities) at high systemic exposures. There are no adequate well-controlled studies in pregnant women. Risk to fetus cannot be ruled out; use only if potential benefit justifies potential risk. First trimester: limited data, theoretical risk based on animal findings. Second and third trimesters: may cause uterine relaxation and delay labor; avoid use near term unless clearly needed.
AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theophylline crosses the placenta and can cause fetal tachycardia, jitteriness, and irritability; apneic episodes and respiratory failure reported in neonates exposed near term. Risk of preterm labor and low birth weight associated with maternal asthma exacerbation.
It is unknown if formoterol is excreted in human breast milk. No M/P ratio available. In lactating rats, formoterol was detected in milk. Because many drugs are excreted in human milk, caution is advised. Decision to discontinue nursing or drug should consider importance of drug to mother. Consider alternative therapies with more breastfeeding safety data.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.67. Peak milk levels occur 1-2 hours after maternal dosing. Estimated infant dose is about 1-10% of maternal weight-adjusted dose. Caution: irritability and jitteriness reported in breastfed infants. Avoid breastfeeding if maternal serum theophylline levels exceed 20 mcg/m L.
No specific dose adjustments recommended for pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may reduce systemic exposure, but standard dosing is generally maintained. Use lowest effective dose to control asthma. Avoid use during labor and delivery due to tocolytic effect.
Pregnancy may increase theophylline clearance (especially in second and third trimesters) due to increased renal perfusion and hepatic metabolism. Dose adjustments often required to maintain therapeutic levels. Initiate at standard dose and titrate based on serum levels and clinical response. Postpartum clearance decreases rapidly; doses should be reduced to pre-pregnancy levels within 2-4 weeks after delivery.
Formoterol is a long-acting beta-agonist (LABA) with rapid onset (within 5 minutes). Must not be used as monotherapy for asthma without concomitant inhaled corticosteroid. Do not use for acute bronchospasm; short-acting beta-agonists are preferred. Rinse mouth after inhalation to prevent thrush and hoarseness. Monitor for paradoxical bronchospasm, tachyphylaxis, and cardiovascular effects. Can be used once or twice daily depending on formulation.
AEROLATE (theophylline) has a narrow therapeutic index; monitor serum levels (target 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease or seizure disorders unless essential. Caution with hepatic impairment, heart failure, and in elderly due to reduced clearance. Drug interactions: cimetidine, fluoroquinolones, macrolides, and CYP1A2 inhibitors increase levels; smoking and rifampin decrease levels.
Do not use Foradil Certihaler to relieve sudden breathing problems; always have a rescue inhaler (e.g., albuterol) available.,Use exactly as prescribed; do not skip doses or use more than prescribed.,Rinse your mouth with water after each use to prevent mouth infection and hoarseness.,Tell your doctor if you have heart problems, high blood pressure, seizures, or thyroid disease.,If asthma, always use this medication with an inhaled corticosteroid; never use LABA alone.,Seek medical help if your symptoms worsen or rescue inhaler does not work well.,Store at room temperature away from moisture and heat. Keep cap on when not in use.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not smoke or stop smoking without informing your doctor, as smoking affects the drug's metabolism.,Keep a list of all medications you take, including over-the-counter drugs and herbal supplements.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FORADIL CERTIHALER vs AEROLATE, answered by our medical review team.
FORADIL CERTIHALER is a Bronchodilator that works by Formoterol is a long-acting beta2-adrenergic receptor agonist that stimulates intracellular adenyl cyclase, increasing cyclic AMP production and causing bronchodilation.. AEROLATE is a Bronchodilator that works by Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FORADIL CERTIHALER and AEROLATE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FORADIL CERTIHALER is: One inhalation (12 mcg) twice daily via oral inhalation.. The standard adult dose of AEROLATE is: For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FORADIL CERTIHALER and AEROLATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FORADIL CERTIHALER is classified as Category C. Formoterol fumarate (FORADIL CERTIHALER) is classified as FDA Pregnancy Category C. In animal studies, formoterol caused fetal malformations (e.g., omphalocele, skeletal abnormalit. AEROLATE is classified as Category C. AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.